PG11047 demonstrated an activity pattern consistent with cytostatic activity against the 22 cell lines of the PPTP in vitro panel (see Table below).

A typical dose response pattern is shown at the left and illustrates the non-zero plateau in T/C% at higher concentrations that typifies the response to cytostatic agents using the T/C endpoint.

The median EC50 for PG11047 against the entire panel was 72.5 nM. The median EC50 for PG11047 against the cell lines of the PPTP in vitro panel (see Table below).

The median EC50 for PG11047 on the entire panel to that of each cell line

The median EC50 for PG11047 against the PPTP's solid tumor panels, with the best response for most panels being somewhat less sensitive than the remaining cell lines studied.

PG11047 demonstrated limited activity against the PPTP's in vivo solid tumor panels, with the best response for most panels being progressive disease with growth delay (PD2).

There was no obvious histotype selectivity for PG11047 among the PPTP in vivo panels, as the 5 xenografts with significant growth delay were spread across 4 different tumor panels.

The single case of tumor regression occurred in an ependymoma xenograft.

PG11047 showed an activity pattern consistent with cytostasis against the cell lines of the PPTP in vitro panel, with the Ewing sarcoma cell lines appearing somewhat more sensitive and the neuroblastoma cell lines somewhat less sensitive than the remaining cell lines studied.